Get started
Author

Giovanni Chinellato

Observed names: G Chinellato, G. Chinellato
ORCID: 0009-0001-7091-8672
Observed ORCID: 0009-0001-7091-8672
OpenAlex ID: A5092240933
Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant Schizophrenia
2023 · Ravi Anand, Alessio Turolla, et al. · The International Journal of Neuropsychopharmacology · 21
PDF
Efficacy and safety of evenamide, a glutamate modulator, added to a second-generation antipsychotic in inadequately/poorly responding patients with chronic schizophrenia: Results from a randomized, double-blind, placebo-controlled, phase 3, international clinical trial
2024 · Ravi Anand, Alessio Turolla, et al. · Neuropharmacology · 15
Therapeutic Effect of Evenamide, a Glutamate Inhibitor, in Patients With Treatment-Resistant Schizophrenia (TRS): Final, 1-Year Results From a Phase 2, Open-Label, Rater-Blinded, Randomized, International Clinical Trial
2024 · Ravi Anand, Alessio Turolla, et al. · The International Journal of Neuropsychopharmacology · 9
PDF
Adjunctive treatment with evenamide, a glutamate modulator, is associated with clinically meaningful benefits in patients with treatment-resistant schizophrenia and inadequate response to antipsychotics: recent clinical findings from randomized trials
2026 · Ravi Anand, Alessio Turolla, et al. · Therapeutic Advances in Psychopharmacology · 2
545. Targeting negative and cognitive symptoms in schizophrenia: discussion of novel preclinical and clinical findings with evenamide
2026 · R Anand, A Turolla, et al. · The International Journal of Neuropsychopharmacology
526. Translating glutamate modulation into clinical advances for patients with treatment-resistant schizophrenia: challenges and updates from the ENIGMA-TRS phase 3 program
2026 · R Anand, A Turolla, et al. · The International Journal of Neuropsychopharmacology
PDF
Unique benefits of evenamide on social functioning and life engagement in patients with TRS, confirmed in a placebo-controlled study in inadequate responders
2026 · R. Anand, A. Turolla, et al. · European Psychiatry
PDF
Effects of evenamide in a neurodevelopmental animal model of schizophrenia suggest potential sustained clinical benefit
2026 · R. Anand, A. Turolla, et al. · European Psychiatry
PDF
ENIGMA-TRS phase 3 trial: designing and implementing a global study of evenamide in treatment-resistant schizophrenia
2026 · R. Anand, A. Turolla, et al. · European Psychiatry
PDF
Telepharmacy-supported multidisciplinary management and clinical outcomes in patients with transthyretin amyloid cardiomyopathy treated with tafamidis: a real-world study
2026 · L. Cordiano, D. Condello, et al. · Clinical Research in Cardiology
Evenamide Phase 3 Program: Study 023 (ENIGMA-TRS) evaluates the efficacy of add-on glutamate modulation in patients with documented treatment-resistant schizophrenia
2026 · R. Anand, A. Turolla, et al. · Neuroscience Applied
Glutamate modulation by evenamide produces statistically significant and clinically relevant improvement in patients with treatment-resistant schizophrenia
2026 · R. Anand, A. Turolla, et al. · Neuroscience Applied
297. Design of a Phase 3, Potentially Pivotal, International, Randomized, Double-blind, Placebo-controlled Trial With Evenamide, a Glutamate Modulator, Add-on to Sga in Patients With Treatment-resistant Schizophrenia
2025 · R Anand, A Turolla, et al. · The International Journal of Neuropsychopharmacology
PDF
315. Evenamide, a Glutamate Modulator, Provided Statistically Significant Benefits When Added to Sga in Patients With Schizophrenia: Phase 2/3, International, Randomized, Double-blind, Placebo-controlled Study Results
2025 · R Anand, A Turolla, et al. · The International Journal of Neuropsychopharmacology
PDF
Efficacy and Safety of Evenamide, a glutamate modulator: Results from a Phase 2/3, international, randomized, double-blind, placebo-controlled add-on trial
2025 · R. Anand, A. Turolla, et al. · European Psychiatry
PDF
Phase 3 program of evenamide, a glutamate release modulator, as add-on in patients with treatment-resistant schizophrenia: design of a potentially pivotal, international, randomized, double-blind, placebo-controlled trial
2025 · R. Anand, A. Turolla, et al. · European Psychiatry
PDF
Evenamide as Add-on Treatment for Patients With Chronic Schizophrenia Not Responding Adequately to Their Current Antipsychotic Medication: Results of a Potentially Pivotal, Phase Ii/iii, International, Randomized, Double Blind, Placebo- Controlled Trial
2025 · *Ravi Anand, Alessio Turolla, et al. · The International Journal of Neuropsychopharmacology
Evenamide as Add-on Treatment for Treatment-resistant Schizophrenia (trs) Patients Not Benefiting From Antipsychotics: Design of a Phase 3, Potentially Pivotal, International, Randomized, Double-blind, Placebo-controlled Clinical Trial
2025 · *Ravi Anand, Alessio Turolla, et al. · The International Journal of Neuropsychopharmacology
PDF
Remarkable Efficacy of Evenamide, a Glutamate Antagonist, as an Add-on to Antipsychotics in Patients With Treatment Resistant Schizophrenia (trs): Results From a One-year, Open- Label, Dose-comparative, Randomized, Treatment Trial
2025 · *Ravi Anand, Alessio Turolla, et al. · The International Journal of Neuropsychopharmacology
Evenamide, as an Add-on to Antipsychotics, Produces Long- Lasting Clinically Meaningful Benefit and Converts Treatment- Resistant Schizophrenia (trs) Patients Into a Responsive State: 6-month Results From an Ongoing International Randomized Study
2025 · *Ravi Anand, Alessio Turolla, et al. · The International Journal of Neuropsychopharmacology
PDF
Achievement of clinically meaningful response and remission in treatment-resistant schizophrenia patients: results from a long-term international study with evenamide add-on
2024 · R. Anand, A. Turolla, et al. · Neuroscience Applied
Evenamide as an add-on to antipsychotics demonstrates significant efficacy in patients with schizophrenia in a potentially pivotal randomized placebo-controlled trial
2024 · R. Anand, A. Turolla, et al. · Neuroscience Applied
Evenamide, as an add-on to antipsychotics, benefits patients with treatment resistant schizophrenia: 6-month results from an ongoing international randomised study
2023 · R. Anand, A. Turolla, et al. · Neuroscience Applied
Evenamide, add-on to antipsychotics, benefits patients with treatment-resistant schizophrenia: final dose-wise results from a Pilot, Phase II, multinational, randomized study
2023 · R. Anand, A. Turolla, et al. · Neuroscience Applied
Evenamide as add-on treatment for treatment-resistant schizophrenia patients not benefiting from antipsychotics: design of an international potentially pivotal clinical trial
2023 · R. Anand, A. Turolla, et al. · Neuroscience Applied
Works count: 27
Citation count: 47
H-index: 3
I10-index: 2
Year
Topic
Type